116 related articles for article (PubMed ID: 15389815)
1. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model.
Uchida K; Masumori N; Takahashi A; Itoh N; Tsukamoto T
Prostate; 2005 Jan; 62(1):40-8. PubMed ID: 15389815
[TBL] [Abstract][Full Text] [Related]
2. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.
Uchida K; Masumori N; Takahashi A; Itoh N; Kato K; Matusik RJ; Tsukamoto T
Prostate; 2006 Apr; 66(5):536-45. PubMed ID: 16372327
[TBL] [Abstract][Full Text] [Related]
3. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
4. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
5. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line.
Masumori N; Tsuchiya K; Tu WH; Lee C; Kasper S; Tsukamoto T; Shappell SB; Matusik RJ
J Urol; 2004 Jan; 171(1):439-42. PubMed ID: 14665950
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
9. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
[TBL] [Abstract][Full Text] [Related]
11. The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate.
Palmer J; Venkateswaran V; Fleshner NE; Klotz LH; Cox ME
Prostate; 2008 Mar; 68(4):345-53. PubMed ID: 18188867
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo.
Palmer J; Ernst M; Hammacher A; Hertzog PJ
Prostate; 2005 Feb; 62(3):282-9. PubMed ID: 15389784
[TBL] [Abstract][Full Text] [Related]
13. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in prostatic carcinoma: an update.
di Sant'Agnese PA
Prostate Suppl; 1998; 8():74-9. PubMed ID: 9690666
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation in human prostatic tumor models.
Noordzij MA; van Weerden WM; de Ridder CM; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1996 Sep; 149(3):859-71. PubMed ID: 8780390
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
18. Malignant transformation in a nontumorigenic human prostatic epithelial cell line.
Hayward SW; Wang Y; Cao M; Hom YK; Zhang B; Grossfeld GD; Sudilovsky D; Cunha GR
Cancer Res; 2001 Nov; 61(22):8135-42. PubMed ID: 11719442
[TBL] [Abstract][Full Text] [Related]
19. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells.
Untergasser G; Plas E; Pfister G; Heinrich E; Berger P
Prostate; 2005 Sep; 64(4):419-29. PubMed ID: 15800938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
